A Phase 2 interventional study of Zoledronic Acid; Letrozole in Breast Cancer, sponsored by Novartis. Completed at 10 sites in Canada. Open to female participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2017-03-01.
Sponsored by Novartis · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing Zoledronic Acid in Breast Neoplasms — none open to participants now, 2 under way, 1 of them phase 3. Zoledronic Acid · Breast Neoplasms.
Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, this one is the 23rd largest by planned enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2005, is one of 11 in phase 2, and was the 17th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →None of the 59 studies testing Zoledronic Acid in Breast Neoplasms is open now. The open studies under Breast Neoplasms, anywhere →
Zoledronic Acid: first FDA approval 2001 (ZOMETA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 65 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 16 · Phase 3 27 · Phase 4 11
First in 1999; this study’s year is marked. 8 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 190 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 98 across the 56 interventional studies. Of the 52 that completed or were terminated, 21 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 59 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
199 studies in Breast Neoplasms by Novartis: 16 open now, 30 under way, 4 of them phase 3. Of 160 finished, 74 (46%) have results posted.
Among the 199 studies in Breast Neoplasms by Novartis, this one is the 61st largest by planned enrollment of the 155 interventional ones that give a count, is one of 10 that started in 2005, is one of 39 in phase 2, and was the 19th registered.
Novartis’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 59 studies testing Zoledronic Acid in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 199 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
This study is to measure the extent of tumor shrinkage when Letrozole and Zoledronic Acid are given before surgery to newly diagnosed post-menopausal women with early breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Other protocol-defined exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug pages: Zoledronic Acid · Letrozole
Clinical response at 24 weeks
Clinical response at 16 weeks
Clinical benefit at 16 weeks
Clinical benefit at 24 weeks
Rate of breast conserving surgery in both arms
Rate of complete pathological response
Biomarkers
The record gives a start of Sep 2005 and a primary completion of Mar 2007. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zoledronic Acid · Letrozole